Asset Details
Do you wish to reserve the book?
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Do you wish to request the book?
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
2008
Overview
The CCR5 coreceptor may be a therapeutic target to block HIV infection. HIV-1–infected patients who had received previous antiretroviral treatment were enrolled in one of two phase 3, placebo-controlled, double-blind international studies of treatment with maraviroc (a CCR5 antagonist). Maraviroc significantly lowered the HIV-1 viral load and increased the CD4 cell count at 48 weeks.
The CCR5 coreceptor may be a therapeutic target to block HIV infection. In two studies, maraviroc (a CCR5 antagonist) significantly lowered the HIV-1 viral load and increased the CD4 cell count at 48 weeks.
For the past decade, treatment of human immunodeficiency virus type 1 (HIV-1) has consisted of a multiple-drug regimen targeting one or more of three HIV-1 proteins: reverse transcriptase, protease, and the glycoprotein envelope subunit gp41.
1
Although these antiretroviral combinations are successful in suppressing viral replication and delaying disease progression, drug resistance and toxic effects may occur.
2
–
4
There is therefore a need for better-tolerated, convenient antiretroviral agents with reduced toxicity and activity against multidrug-resistant viruses.
Agents with novel mechanisms of action provide options for patients with drug-resistant virus.
4
CC chemokine receptor 5 (CCR5) is an attractive therapeutic target, since people . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Anti-Retroviral Agents - adverse effects
/ Anti-Retroviral Agents - therapeutic use
/ Anti-Retroviral Agents/adverse effects/therapeutic use
/ Biological and medical sciences
/ Cyclohexanes - adverse effects
/ Cyclohexanes - therapeutic use
/ Cyclohexanes/adverse effects/therapeutic use
/ Female
/ HIV
/ HIV Fusion Inhibitors - adverse effects
/ HIV Fusion Inhibitors - therapeutic use
/ HIV Fusion Inhibitors/adverse effects/therapeutic use
/ HIV Infections - drug therapy
/ HIV Infections/drug therapy/virology
/ Human immunodeficiency virus
/ Humans
/ Immunologie & maladie infectieuse
/ Immunology & infectious disease
/ Male
/ Receptors, CCR5/antagonists & inhibitors
/ Sciences de la santé humaine
/ Triazoles/adverse effects/therapeutic use
